Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Vinorelbine Regimens in Metastatic Breast Cancer
NCT00532623Phase 2Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2004
- Primary completion
- Sep 2006
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of gemcitabine and vinorelbine in breast cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall Response Rate at 3 years. Started May 2004; status: completed.
02
Drugs
gemcitabinevinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00532623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00532623.